Socioeconomic Factors and Access to Quality Care Affect Breast Cancer Survival

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

Race does not appear to be a major factor in breast cancer survival when information on stage of disease, income level, education, and access to care also are reviewed, a number of studies show.

Race does not appear to be a major factor in breast cancer survivalwhen information on stage of disease, income level, education,and access to care also are reviewed, a number of studies show.

African-American women are at least one and a half times morelikely to be diagnosed with later-stage disease, says Dr. LoriPierce, Assistant Professor of Radiation Oncology at the Universityof Michigan Medical School in Ann Arbor. "In addition, raceis frequently synonymous with poverty, and poverty is synonymouswith lower education level. This lower education, lower incomegroup has the least access to care," she says.

It's a vicious circle, says Dr. Pierce. "The best way tobreak through the circle is to make mammography screening, qualitytreatment, and treatment follow-up more available to African-Americanwomen," she says.

Quality treatment also is essential, she says. "I've hadAfrican-American women tell me they avoid screening for breastcancer because they are afraid they'll have cancer, and cancermeans they'll have to have their breast removed," she says.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.